Levodopa Benefits Neovascular Age-Related Macular Degeneration
TUESDAY, Sept. 15, 2020 -- Levodopa is a safe and well-tolerated treatment for neovascular age-related macular degeneration (nAMD) and improves visual outcomes, according to a study recently published in The American Journal of Medicine.
Anna G.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 15, 2020 Category: Pharmaceuticals Source Type: news
Levodopa may improve vision in patients with macular degeneration
(Elsevier) Investigators have determined that treating patients with an advanced form of age-related macular degeneration (AMD) with levodopa, a safe and readily available drug commonly used to treat Parkinson's disease, stabilized and improved their vision. It reduced the number of treatments necessary to maintain vision, and as such, will potentially reduce the burden of treating the disease, financially and otherwise. Their findings appear in The American Journal of Medicine, published by Elsevier. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 10, 2020 Category: International Medicine & Public Health Source Type: news
Oleh Hornykiewicz, Who Discovered Parkinson ’s Treatment, Dies at 93
His research into dopamine led to the mainstay treatment still used today to treat millions of people with Parkinson ’s. (Source: NYT Health)
Source: NYT Health - June 12, 2020 Category: Consumer Health News Authors: Sam Roberts Tags: Parkinson ' s Disease Dopamine Deaths (Obituaries) Research Hornykiewicz, Oleh L-dopa Levodopa Source Type: news
FDA Clears Opicapone (Ongentys) as Add-On Therapy in PD FDA Clears Opicapone (Ongentys) as Add-On Therapy in PD
Opicapone is an oral COMT inhibitor approved as add-on therapy for patients with Parkinson disease who experience ' off ' periods while receiving a stable levodopa/carbidopa regimen.FDA Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - April 28, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news
Neurocrine Biosciences Announces FDA Approval of Once-Daily ONGENTYS(R) (opicapone) as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes
ONGENTYS, the First and Only Approved Once-Daily COMT Inhibitor, Decreases "Off" Time and Increases "On" Time Without Troublesome Dyskinesia When Added to Levodopa/Carbidopa in Patients with Parkinson's Disease
Neurocrine Biosciences... Biopharmaceuticals, Neurology, FDA Neurocrine Biosciences, ONGENTYS, opicapone, Parkinson's Disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 27, 2020 Category: Pharmaceuticals Source Type: news
Accidental Modopar poisoning in a two-year-old child: a case report - Lahlou A, Benlamkaddem S, Berdai MA, Harandou M.
Levodopa is a dopamine precursor and a mainstay treatment in the management of Parkinson's disease. Its side effects induce dyskinesia, nausea, vomiting, and orthostatic hypotension. Acute levodopa acute poisoning is uncommon, with only a few reported case... (Source: SafetyLit)
Source: SafetyLit - January 11, 2020 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news
levodopa-carbidopa, Sinemet, Sinemet CR, Parcopa
Title: levodopa-carbidopa, Sinemet, Sinemet CR, ParcopaCategory: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 12/17/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - December 17, 2019 Category: Drugs & Pharmacology Source Type: news
RightEye Has “Breakthrough” in Its Vision for Parkinson’s Test
There could soon be an eye test to aid in the assessment of Parkinson’s disease. FDA has recently granted breakthrough device designation to a technology designed by RightEye that uses objective eye movement measurements to help detect the neurological disease.
If the RightEye Vision System could gain a nod from FDA for detection, it would be a gamechanger because currently, no single test is capable of definitively diagnosing Parkinson's disease. Doctors instead rely on a variety of neurological examinations designed to confirm the clinical diagnosis, and misdiagnosis remains a continuing iss...
Source: MDDI - December 3, 2019 Category: Medical Devices Authors: Omar Ford Tags: Regulatory and Compliance Source Type: news
Vitamins for Depression
In trying to cope with the debilitating symptoms of depression, people often turn to vitamins, supplements, herbs, or home remedies first. And it’s no wonder — such efforts to alleviate symptoms are often far less expensive and easier to obtain. For some, it may be a part of their rationalization that their depression “isn’t all that bad,” if it can be treated with vitamins and supplements.
Many people find relief in taking vitamins and supplements for depression. It is also one of the most well-researched topics, so we know what the science has to say about the efficacy of such treatments. Bu...
Source: Psych Central - September 3, 2019 Category: Psychiatry Authors: John M. Grohol, Psy.D. Tags: Depression Diet & Nutrition General Medications Miscellaneous Drugs supplements for depression vitamins for depression Source Type: news
Nourianz Approved to Treat'Off' Episodes in Parkinson Disease
WEDNESDAY, Aug. 28, 2019 -- Nourianz (istradefylline) tablets have been approved as an add-on treatment to levodopa/carbidopa for adults with Parkinson disease experiencing " off " episodes, the U.S. Food and Drug Administration announced... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 28, 2019 Category: General Medicine Source Type: news
FDA OKs Istradefylline for Parkinson's Disease'Off' Episodes FDA OKs Istradefylline for Parkinson's Disease'Off' Episodes
Oral istradefylline (Nourianz) reduces"off" episodes when added to levodopa/carbidopa in patients with Parkinson ' s disease.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - August 28, 2019 Category: Drugs & Pharmacology Tags: Neurology & Neurosurgery News Alert Source Type: news
FDA Approves Nourianz (istradefylline) as an Add-On Drug to Treat Off Episodes in Adults with Parkinson ’s Disease
August 27, 2019 -- The U.S. Food and Drug Administration today approved Nourianz (istradefylline) tablets as an add-on treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) experiencing " off " episodes. An " off " ... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 28, 2019 Category: Drugs & Pharmacology Source Type: news
A Wearable Device Is Changing the Way Clinicians Manage Parkinson & #039;s Patients
A recently published study in Functional Neurology suggests that using data from an FDA-cleared watch-like device called the Personal KinetiGraph (PKG) provides an objective and more effective approach to assessing motor fluctuations in patients with Parkinson's disease (PD) compared with patient-reported motor diaries.
“Motor fluctuations, including 'wearing-off' and dyskinesia, are associated with increased disease severity and disability, and PD patients experience decreased quality of life as their response to medical therapy becomes less predictable,†said EchoÂ&nb...
Source: MDDI - August 2, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Digital Health Source Type: news
CHMP Backs Inhaled Levodopa (Inbrija) for Parkinson's'Off' Episodes CHMP Backs Inhaled Levodopa (Inbrija) for Parkinson's'Off' Episodes
Levodopa inhalation powder is safe and effective in improving motor function during ' off ' periods in patients with Parkinson ' s disease.International Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - July 26, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news
Freezing of gait and postural instability: the unpredictable response to levodopa in Parkinson's disease - Moreira F, Rebelo Gomes I, Janu ário C.
Freezing of gait (FOG) and postural instability are challenging motor symptoms that present a serious therapeutic dilemma in Parkinson's disease. Appropriate distinction between FOG subtypes may be difficult during routine clinical visits, as shown in the ... (Source: SafetyLit)
Source: SafetyLit - July 26, 2019 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
